Evidence map›Paper›PMID 18503496›Full record

Trial reportPediatric diabetes2008

Enhanced levels of cow's milk antibodies in infancy in children who develop type 1 diabetes later in childhood.

Kristiina Luopajärvi, Erkki Savilahti, Suvi M Virtanen, Jorma Ilonen, Mikael Knip, Hans K Akerblom, Outi Vaarala

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Pediatric diabetes, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03032354 (Effect of Lactobacillus Rhamnosus GG and Bifidobacterium Lactis BB 12 on Beta-cell Function in Children With Newly Diagnosed Type 1 Diabetes - a Randomized Controlled Trial), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03032354 phase4unknown statusnot on this mapstarted 2017, after this paper: background citation

Effect of Lactobacillus Rhamnosus GG and Bifidobacterium Lactis BB 12 on Beta-cell Function in Children With Newly Diagnosed Type 1 Diabetes - a Randomized Controlled Trial

TypeinterventionalSponsorMedical University of WarsawRan2017 to 2018Enrolled96ConditionsDiabetes Mellitus, Type 1ArmsLactobacillus rhamnosus GG and Bifidobacterium lactis BB12, Placebo, (Placebo group)
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Early-onset colorectal cancer: initial clues and current views.Nature reviews. Gastroenterology & hepatology · 2020
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Gut microbiome in type 1 diabetes: A comprehensive review.Diabetes/metabolism research and reviews · 2018
    Review
  16. Article
  17. Review
  18. Review
  19. Human intestinal microbiota and type 1 diabetes.Current diabetes reports · 2013
    Review
  20. Prevention or acceleration of type 1 diabetes by viruses.Cellular and molecular life sciences : CMLS · 2013
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Kristiina LuopajärviHospital for Children and Adolescents, University of Helsinki, Helsinki, Finland. kristiina.luopajarvi@hus.fi
Erkki Savilahti
Suvi M Virtanen
Jorma Ilonen
Mikael Knip
Hans K Akerblom
Outi Vaarala
University of Helsinki · FITampere University · FIInstitute for Molecular Medicine Finland · FIUniversity of Eastern Finland · FI

Funding

Trial to Reduce IDDM in the Genetically at Risk StudyU01HD040364 · NICHD · UNIVERSITY OF HELSINKI · PI KNIP, MIKAEL · 2001 to 2015
$32.7M
NICHD NIH HHS U01 HD040364
6 · The paper itself

Abstract

backgroundEarly exposure to cow's milk (CM) proteins have been implicated in the pathogenesis of type 1 diabetes (T1D).

objectiveWe analyzed the development of the humoral immune response to dietary CM proteins in early childhood and its relation to later T1D. SUBJECTS AND

methodsWe studied a subgroup of 94 children randomized to be weaned to a CM-based infant formula in the trial to reduce insulin-dependent diabetes mellitus in the genetically at risk (TRIGR) pilot study. All subjects carried human leukocyte antigen-conferred T1D susceptibility and had an affected first-degree relative. After 7 years of follow-up, 8 subjects had progressed to T1D, 15 had at least one disease-associated autoantibody, and 71 remained autoantibody negative (controls). Immunoglobulin (Ig) G and IgA class antibodies to whole CM formula, beta-lactoglobulin (BLG), bovine serum albumin, and alpha-casein and IgG antibodies to bovine insulin (BI) were measured with enzyme-linked immunosorbent assays from sequential samples.

resultsThe children with later T1D showed increased IgG levels to BLG from 3 to 18 months of age (p = 0.028) and enhanced IgA levels to CM formula at the age of 9 months (p = 0.022) compared with controls. In the children with an affected father or sibling, IgG antibodies to BI were higher in autoantibody-positive subjects than in autoantibody-negative subjects at 18 months of age (p = 0.022).

conclusionAn enhanced humoral immune response to various CM proteins in infancy is seen in a subgroup of those children who later progress to T1D. Accordingly, a dysregulated immune response to oral antigens is an early event in the pathogenesis of T1D.

Indexed as

AnimalsAutoantibodiesBreast FeedingCattleChildChild, PreschoolDiabetes Mellitus, Type 1FemaleGenetic Predisposition to DiseaseHLA-DQ AntigensHLA-DQ beta-ChainsHumansImmunoglobulin AImmunoglobulin GInfantInfant FormulaAutoantibodiesHLA-DQ AntigensHLA-DQB1 antigenHLA-DQ beta-ChainsImmunoglobulin AImmunoglobulin GInsulin AntibodiesMilk ProteinsTetanus Toxoid

Identifiers

PMID18503496
PMCPMC4225539
OpenAlexW2007595794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.